Author:
Thigpen Tate,duBois Andreas,McAlpine Jessica,DiSaia Philip,Fujiwara Keiichi,Hoskins William,Kristensen Gunnar,Mannel Robert,Markman Maurie,Pfisterer Jacobus,Quinn Michael,Reed Nick,Swart Ann Marie,Berek Jonathan,Colombo Nicoletta,Freyer Gilles,Gallardo Dolores,Plante Marie,Poveda Andres,Rubinstein Lawrence,Bacon Monica,Kitchener Henry,Stuart Gavin C.E.
Abstract
At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients.A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)?A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials?A3: Is the 2004 GCIG-recommended standard comparator arm still valid?A4: What is the role of modifying dose, schedule, and delivery of chemotherapy?A5: What role does surgery play today?
Subject
Obstetrics and Gynecology,Oncology
Cited by
81 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献